Patterson Companies Inc (PDCO) investors sentiment decreased to 1 in Q4 2017. It’s down -0.25, from 1.25 in 2017Q3. The ratio has worsened, as 170 hedge funds increased and started new holdings, while 170 sold and decreased holdings in Patterson Companies Inc. The hedge funds in our database now own: 87.24 million shares, down from 88.39 million shares in 2017Q3. Also, the number of hedge funds holding Patterson Companies Inc in top ten holdings decreased from 1 to 0 for a decrease of 1. Sold All: 57 Reduced: 113 Increased: 104 New Position: 66.
The stock of Aimmune Therapeutics, Inc. (NASDAQ:AIMT) is a huge mover today! The stock decreased 1.33% or $0.42 during the last trading session, reaching $31.07. About 159,006 shares traded. Aimmune Therapeutics, Inc. (NASDAQ:AIMT) has risen 29.28% since April 16, 2017 and is uptrending. It has outperformed by 17.73% the S&P500.The move comes after 5 months negative chart setup for the $1.80B company. It was reported on Apr, 16 by Barchart.com. We have $29.83 PT which if reached, will make NASDAQ:AIMT worth $72.12 million less.
Patterson Companies, Inc. distributes and sells dental and animal health products in the United States, the United Kingdom, and Canada. The company has market cap of $2.14 billion. It operates through Dental and Animal Health divisions. It has a 8.96 P/E ratio. The companyÂ’s Dental segment offers consumable products, such as infection control, restorative materials, hand instruments, and sterilization products; basic and advanced technology dental equipment; patient education systems; and office forms and stationery.
Analysts await Patterson Companies, Inc. (NASDAQ:PDCO) to report earnings on May, 24. They expect $0.34 earnings per share, down 50.72% or $0.35 from last year’s $0.69 per share. PDCO’s profit will be $31.43 million for 17.04 P/E if the $0.34 EPS becomes a reality. After $0.43 actual earnings per share reported by Patterson Companies, Inc. for the previous quarter, Wall Street now forecasts -20.93% negative EPS growth.
Fairpointe Capital Llc holds 2.71% of its portfolio in Patterson Companies, Inc. for 3.97 million shares. Shapiro Capital Management Llc owns 3.33 million shares or 2.63% of their US portfolio. Moreover, Sector Gamma As has 1.84% invested in the company for 303,132 shares. The Texas-based Highland Capital Management Lp has invested 1.6% in the stock. Olstein Capital Management L.P., a New York-based fund reported 327,088 shares.
The stock increased 1.22% or $0.28 during the last trading session, reaching $23.17. About 358,978 shares traded. Patterson Companies, Inc. (PDCO) has declined 51.49% since April 16, 2017 and is downtrending. It has underperformed by 63.04% the S&P500.
Since January 1, 0001, it had 0 insider buys, and 1 sale for $27,285 activity.
Among 4 analysts covering Aimmune Therapeutics (NASDAQ:AIMT), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aimmune Therapeutics had 5 analyst reports since August 31, 2015 according to SRatingsIntel. The rating was initiated by Credit Suisse on Monday, August 31 with “Outperform”. The stock of Aimmune Therapeutics, Inc. (NASDAQ:AIMT) has “Overweight” rating given on Monday, August 31 by Piper Jaffray. The company was initiated on Monday, August 31 by Bank of America. The firm has “Overweight” rating by Piper Jaffray given on Tuesday, November 17. The stock of Aimmune Therapeutics, Inc. (NASDAQ:AIMT) has “Mkt Outperform” rating given on Monday, September 26 by JMP Securities.
Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies in the United States and Europe. The company has market cap of $1.80 billion. The Company’s lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy. It currently has negative earnings. Aimmune Therapeutics, Inc. has strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics.